BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/13/2018 6:32:35 AM | Browse: 1053 | Download: 1964
 |
Received |
|
2018-08-29 02:03 |
|
Peer-Review Started |
|
2018-08-29 07:12 |
|
To Make the First Decision |
|
2018-10-08 02:56 |
|
Return for Revision |
|
2018-10-14 07:09 |
|
Revised |
|
2018-11-18 19:01 |
|
Second Decision |
|
2018-12-06 10:04 |
 |
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2018-12-07 03:32 |
|
Articles in Press |
|
2018-12-07 03:32 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2018-12-12 03:47 |
|
Publish the Manuscript Online |
|
2018-12-13 06:32 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Observational Study |
| Article Title |
Loss of efficacy and safety of the switch from infliximab original to infliximab biosimilar (CT-P13) in patients with inflammatory bowel disease
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
María Fernanda Guerra Veloz, Federico Argüelles-Arias, Luisa Castro Laria, Belen Maldonado Perez, Antonio Benitez Roldan, Raul Perea Amarillo, Vicente Merino Bohorquez, Miguel Angel Calleja, Angel Caunedo Alvarez and Angel Vilches Arenas |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Federico Argüelles-Arias, PhD, Doctor, Doctor, Professor, Department of Gastroenterology, University Hospital Virgen Macarena, Dr. Fedriani 3, seville 41007, Spain. farguelles@telefonica.net |
| Key Words |
Crohn’s disease; Ulcerative colitis; CT-P13; Inflammatory bowel disease; Biosimilar agent; Infliximab original; Efficacy |
| Core Tip |
Although not strictly necessary, there are few studies comparing efficacy and safety of the switch from infliximab original (Remicade®) to infliximab biosimilar CT-P13 vs the maintenance of the original infliximab. For this reason, we presented a comparative study with the original infliximab. Our observational study demonstrates the real-life clinical results of efficacy and safety of infliximab original and the efficacy and safety after switching from original infliximab to infliximab biosimilar CT-P13 at the 12 mo follow-up. Our results demonstrate there is no statistical difference in remission rate, secondary loss of response or adverse events between both therapies. |
| Publish Date |
2018-12-13 06:32 |
| Citation |
Guerra Veloz MF, Argüelles-Arias F, Castro Laria L, Maldonado Pérez B, Benítez Roldán A, Perea Amarillo R, Merino Bohórquez V, Calleja MA, Caunedo Álvarez Á, Vilches Arenas Á. Loss of efficacy and safety of the switch from infliximab original to infliximab biosimilar (CT-P13) in patients with inflammatory bowel disease. World J Gastroenterol 2018; 24(46): 5288-5296 |
| URL |
https://www.wjgnet.com/1007-9327/full/v24/i46/5288.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v24.i46.5288 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
